 |
PDBsum entry 3cth
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
|
|
|
|
|
Enzyme class:
|
|
E.C.2.7.10.1
- receptor protein-tyrosine kinase.
|
|
|
|
|
|
|
Reaction:
|
|
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
|
|
|
|
|
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
|
|
|
|
|
|
|
|
|
|
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
|
| |
|
|
Bioorg Med Chem Lett
18:3224-3229
(2008)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.
|
|
Z.W.Cai,
D.Wei,
G.M.Schroeder,
L.A.Cornelius,
K.Kim,
X.T.Chen,
R.J.Schmidt,
D.K.Williams,
J.S.Tokarski,
Y.An,
J.S.Sack,
V.Manne,
A.Kamath,
Y.Zhang,
P.Marathe,
J.T.Hunt,
L.J.Lombardo,
J.Fargnoli,
R.M.Borzilleri.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
A series of acylurea analogs derived from pyrrolopyridine and aminopyridine
scaffolds were identified as potent inhibitors of Met kinase activity. The SAR
at various positions of the two kinase scaffolds was investigated. These studies
led to the discovery of compounds 3b and 20b, which demonstrated favorable
pharmacokinetic properties in mice and significant antitumor activity in a human
gastric carcinoma xenograft model.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
J.Caballero,
M.Quiliano,
J.H.Alzate-Morales,
M.Zimic,
and
E.Deharo
(2011).
Docking and quantitative structure-activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors.
|
| |
J Comput Aided Mol Des,
25,
349-369.
|
|
|
|
|
|
|
Z.Liang,
D.Zhang,
J.Ai,
L.Chen,
H.Wang,
X.Kong,
M.Zheng,
H.Liu,
C.Luo,
M.Geng,
H.Jiang,
and
K.Chen
(2011).
Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase.
|
| |
Bioorg Med Chem Lett,
21,
3749-3754.
|
|
|
|
|
|
|
A.G.Villaseñor,
R.Kondru,
H.Ho,
S.Wang,
E.Papp,
D.Shaw,
J.W.Barnett,
M.F.Browner,
and
A.Kuglstatter
(2009).
Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
|
| |
Chem Biol Drug Des,
73,
466-470.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
C.L.Gibson,
J.K.Huggan,
A.Kennedy,
L.Kiefer,
J.H.Lee,
C.J.Suckling,
C.Clements,
A.L.Harvey,
W.N.Hunter,
and
L.B.Tulloch
(2009).
Diversity oriented syntheses of fused pyrimidines designed as potential antifolates.
|
| |
Org Biomol Chem,
7,
1829-1842.
|
|
|
|
|
|
|
H.Schirok,
R.Kast,
S.Figueroa-Pérez,
S.Bennabi,
M.J.Gnoth,
A.Feurer,
H.Heckroth,
M.Thutewohl,
H.Paulsen,
A.Knorr,
J.Hütter,
M.Lobell,
K.Münter,
V.Geiss,
H.Ehmke,
D.Lang,
M.Radtke,
J.Mittendorf,
and
J.P.Stasch
(2008).
Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
|
| |
ChemMedChem,
3,
1893-1904.
|
|
|
|
|
|
|
I.Kufareva,
and
R.Abagyan
(2008).
Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states.
|
| |
J Med Chem,
51,
7921-7932.
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|
Links
